The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.
I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.
Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.
The beaten-down name is finally lining up as an attractive value play.
In a market filled with charts without a clear stop, ORCL offers that.
Oracle's acquisition bid today for CERN of about $28.3B certainly helped us get there.
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
Here's why I say, don't worry about the Fed, D.C. or inflation, and instead look at this big deal.
It may be time to take some money off the table.
The shares of the food delivery service are climbing after word of a deal to acquire rival Wolt Enterprises, which will expand its presence in Europe.